Functional Near‐Infrared Spectroscopy Reveals Lecanemab‐Induced Neural Changes During the Clock Drawing Test in Alzheimer's Disease

Abstract

Background: Lecanemab, a monoclonal antibody targeting amyloid‐beta (Aβ) aggregates, has shown efficacy in reducing Aβ burden in Alzheimer’s disease (AD). However, its impact on brain function remains understudied.

The paper